Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer.

Literature DB >> 25910705

The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer.

Qinghua Xi¹, Menghui Huang, Yingying Wang, Jianxin Zhong, Rong Liu, Guiqin Xu, Lifei Jiang, Juan Wang, Zheng Fang, Shuyun Yang.

Abstract

Overexpression of cyclin-dependent kinase 1 (CDK1) has been noted to correlation with several human cancers. However, the effects of CDK1 on ovarian cancer development remain unclear. The aim of this study was to examine the effect of CDK1 and related mechanism in the proliferation and resistance to chemotherapeutic drugs of epithelial ovarian cancer (EOC). Immunohistochemical analysis was performed in 119 human ovarian cancer samples, and the data were correlated with clinicopathologic features. Furthermore, Western blot analysis was performed for CDK1 in EOC samples and cell lines to evaluate their protein levels and molecular interaction. Kaplan-Meier survival analysis showed that strong expression of CDK1 exhibited a significant correlation with poor prognosis in human EOC (P = 0.02). Meanwhile, we found that knockdown CDK1 by shCDK1 promoted the apoptosis rate and increased the sensitivity to chemotherapy drugs. Thus, CDK1 might serve as a prognostic marker, and it might be of great value for experimental therapies in EOC.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2015 PMID： 25910705 DOI： 10.1007/s13277-015-3141-8

Source DB: PubMed Journal: Tumour Biol ISSN： 1010-4283

17 in total

Review 1. Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy?

Authors: J M Li; G Brooks
Journal: Eur Heart J Date: 1999-03 Impact factor: 29.983

2. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.

Authors: Xiaolan Zhu; Yuefeng Li; Chanjuan Xie; Xinming Yin; Yueqin Liu; Yuan Cao; Yue Fang; Xin Lin; Yao Xu; Wenlin Xu; Huiling Shen; Jian Wen
Journal: Int J Cancer Date: 2014-04-28 Impact factor: 7.396

3. Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.

Authors: S J Kim; S Nakayama; K Shimazu; Y Tamaki; K Akazawa; F Tsukamoto; Y Torikoshi; T Matsushima; M Shibayama; H Ishihara; S Noguchi
Journal: Ann Oncol Date: 2011-08-04 Impact factor: 32.976

4. Cancer statistics, 2012.

Authors: Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal: CA Cancer J Clin Date: 2012-01-04 Impact factor: 508.702

5. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.

Authors: Poorval M Joshi; Shari L Sutor; Catherine J Huntoon; Larry M Karnitz
Journal: J Biol Chem Date: 2014-02-19 Impact factor: 5.157

6. Millepachine, a novel chalcone, induces G2/M arrest by inhibiting CDK1 activity and causing apoptosis via ROS-mitochondrial apoptotic pathway in human hepatocarcinoma cells in vitro and in vivo.

Authors: Wenshuang Wu; Haoyu Ye; Li Wan; Xiaolei Han; Guangcheng Wang; Jia Hu; Minhai Tang; Xingmei Duan; Yi Fan; Shichao He; Li Huang; Heying Pei; Xuewei Wang; Xiuxia Li; Caifeng Xie; Ronghong Zhang; Zhu Yuan; Yongqiu Mao; Yuquan Wei; Lijuan Chen
Journal: Carcinogenesis Date: 2013-03-07 Impact factor: 4.944

7. Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population.

Authors: H E Lambert; W M Gregory; A E Nelstrop; G J S Rustin
Journal: Int J Gynecol Cancer Date: 2004 Sep-Oct Impact factor: 3.437

8. Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy.

Authors: Mario M Leitao; Amanda Hummer; Don S Dizon; Carol Aghajanian; Martee Hensley; Paul Sabbatini; Ennapadam Venkatraman; David R Spriggs
Journal: Gynecol Oncol Date: 2003-10 Impact factor: 5.482

9. Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance.

Authors: Chunyu Zhang; Abdel G Elkahloun; Matthew Robertson; Joell J Gills; Junji Tsurutani; Joanna H Shih; Junya Fukuoka; M Christine Hollander; Curtis C Harris; William D Travis; Jin Jen; Phillip A Dennis
Journal: PLoS One Date: 2011-08-24 Impact factor: 3.240

10. Sulforaphane induced cell cycle arrest in the G2/M phase via the blockade of cyclin B1/CDC2 in human ovarian cancer cells.

Authors: Chi-Chang Chang; Chao-Ming Hung; Yun-Ru Yang; Mon-Juan Lee; Yi-Chiang Hsu
Journal: J Ovarian Res Date: 2013-06-26 Impact factor: 4.234

25 in total

1. Laryngeal squamous cell carcinoma cell lines show high tolerance for siRNA-mediated CDK1 knockdown.

Authors: Kinga Bednarek; Magdalena Kostrzewska-Poczekaj; Adam Ustaszewski; Joanna Janiszewska; Katarzyna Kiwerska; Julia Paczkowska; Reidar Grenman; Maciej Giefing; Malgorzata Jarmuz-Szymczak
Journal: Am J Cancer Res Date: 2021-05-15 Impact factor: 6.166

2. CDKN2A, CDK1, and CCNE1 overexpression in sebaceous gland carcinoma of eyelid.

Authors: Tatsuya Yunoki; Tetsushi Hirano; Yoshiaki Tabuchi; Yukihiro Furusawa; Misako Torigoe; Takahiko Nakajima; Johji Imura; Atsushi Hayashi
Journal: Int Ophthalmol Date: 2019-09-30 Impact factor: 2.031

3. Recurrent CDK1 overexpression in laryngeal squamous cell carcinoma.

Authors: K Bednarek; K Kiwerska; M Szaumkessel; M Bodnar; M Kostrzewska-Poczekaj; A Marszalek; J Janiszewska; A Bartochowska; J Jackowska; M Wierzbicka; R Grenman; K Szyfter; M Giefing; M Jarmuz-Szymczak
Journal: Tumour Biol Date: 2016-02-24

4. DLEU1 contributes to ovarian carcinoma tumourigenesis and development by interacting with miR-490-3p and altering CDK1 expression.

Authors: Li-Li Wang; Kai-Xuan Sun; Dan-Dan Wu; Yin-Ling Xiu; Xi Chen; Shuo Chen; Zhi-Hong Zong; Xiu-Bo Sang; Yao Liu; Yang Zhao
Journal: J Cell Mol Med Date: 2017-06-09 Impact factor: 5.310

5. Prognostic Value of RNASEH2A-, CDK1-, and CD151-Related Pathway Gene Profiling for Kidney Cancers.

Authors: Chin-An Yang; Hsi-Yuan Huang; Ju-Chen Yen; Jan-Gowth Chang
Journal: Int J Mol Sci Date: 2018-05-28 Impact factor: 5.923

6. CDK1 interacts with iASPP to regulate colorectal cancer cell proliferation through p53 pathway.

Authors: Wei Gan; Hua Zhao; Tiegang Li; Kuijie Liu; Jiangsheng Huang
Journal: Oncotarget Date: 2017-05-11

7. Integrative analyses of gene expression profile reveal potential crucial roles of mitotic cell cycle and microtubule cytoskeleton in pulmonary artery hypertension.

Authors: Jing Luo; Haiyan Li; Zhenwei Liu; Chenlu Li; Ruochen Wang; Jinxia Fang; Saisai Lu; Jing Guo; Xiaochun Zhu; Xiaobing Wang
Journal: BMC Med Genomics Date: 2020-06-26 Impact factor: 3.063

8. Analysis of Differentially Expressed Proteins in Mycobacterium avium-Infected Macrophages Comparing with Mycobacterium tuberculosis-Infected Macrophages.

Authors: Dongjun Yang; Xin Fu; Shiyi He; Xueping Ning; Min Ling
Journal: Biomed Res Int Date: 2017-05-10 Impact factor: 3.411

9. Identification of key genes and pathways in human clear cell renal cell carcinoma (ccRCC) by co-expression analysis.

Authors: Lushun Yuan; Guang Zeng; Liang Chen; Gang Wang; Xiaolong Wang; Xinyue Cao; Mengxin Lu; Xuefeng Liu; Guofeng Qian; Yu Xiao; Xinghuan Wang
Journal: Int J Biol Sci Date: 2018-02-12 Impact factor: 6.580

10. Identification of the potential oncogenes in glioblastoma based on bioinformatic analysis and elucidation of the underlying mechanisms.

Authors: Yong Zhang; Qiming Xia; Jun Lin
Journal: Oncol Rep Date: 2018-06-11 Impact factor: 3.906